title: Editorial Commentary: Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World" Outcomes.
authors.affiliation: Kirby Institute, University of New South Wales Australia, Sydney, Australia.
authors.forename: Marianne
authors.initials: M
authors.lastname: Martinello
authors.affiliation: Kirby Institute, University of New South Wales Australia, Sydney, Australia.
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Dore
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D060085:Coinfection / Q000188:drug therapy; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons
keywords: HCV–HIV coinfection; direct-acting antiviral; real world